Dupilumab treatment decreases hospitalization rate in atopic dermatitis people

Summaries 2 min 282

Font Size

Created On: 19/03/2022

This study was conducted to compare the hospitalization rates in people with moderate to severe atopic dermatitis (AD) treated with dupilumab versus control.

See All

Key take away

In people with moderate to severe atopic dermatitis, treatment with dupilumab was associated with a substantial reduction in the rate of hospitalization.

Background

This study was conducted to compare the hospitalization rates in people with moderate to severe atopic dermatitis (AD) treated with dupilumab versus control.

Method

In this post hoc analysis, a total of 7 randomized, placebo-controlled trials on subjects with atopic dermatitis who were administered with 300 mg dupilumab every 2 weeks (q2w) or weekly (qw); with or without topical corticosteroids, versus placebo for 12, 16 or 52 weeks were evaluated. Overall, 2932 subjects were enrolled and divided into 2 treatment groups: Dupilumab group and Control group including 1841 and 1091 patients respectively. The endpoints studied were hospitalization rates (“all-cause” and “AD-related”) and length of AD-related hospitalizations.

Result

The rates of all-cause hospitalizations, AD-related hospitalizations and overall duration of AD-related hospitalization are shown in Table 1:

Conclusion

The above findings suggest that moderate-to-severe AD patients who were given dupilumab showed reduced rates of all-cause hospitalizations and shorter hospitalization duration when compared to placebo.